CLINICAL TRIALS PROFILE FOR CENTANY

All Clinical Trials for CENTANY

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00179959 ↗	The Impact of Treating Staphylococcus Aureus Infection and Colonization on the Clinical Severity of Atopic Dermatitis	Completed	Johnson & Johnson	Phase 4	2005-09-01	Staphylococcus aureus (S. aureus) infection is perceived not only as a common secondary complication of atopic dermatitis (AD), but also as a culprit in the worsening of this condition. In addition, the recent development of community acquired methicillin-resistant S. aureus (CA-MRSA) has presented a new challenge to our management of AD, both in treatment of acute infections and maintenance therapy. The investigators would like to perform a randomized investigator-blinded placebo-controlled study of children aged 6 months to 17 years with moderate to severe atopic dermatitis with clinical signs of secondary bacterial infection to study: 1) the prevalence of CA-MRSA in our patient population; 2) the relationship of sensitivity of the S. aureus organism cultured from the infected lesion(s) to clinical response to oral cephalexin therapy and severity of the AD; and 3) whether concurrent treatment of S. aureus infection initially with nasal mupirocin ointment and sodium hypochlorite (bleach) baths can result in long-term S. aureus eradication and clinical stability.
NCT00179959 ↗	The Impact of Treating Staphylococcus Aureus Infection and Colonization on the Clinical Severity of Atopic Dermatitis	Completed	Society for Pediatric Dermatology	Phase 4	2005-09-01	Staphylococcus aureus (S. aureus) infection is perceived not only as a common secondary complication of atopic dermatitis (AD), but also as a culprit in the worsening of this condition. In addition, the recent development of community acquired methicillin-resistant S. aureus (CA-MRSA) has presented a new challenge to our management of AD, both in treatment of acute infections and maintenance therapy. The investigators would like to perform a randomized investigator-blinded placebo-controlled study of children aged 6 months to 17 years with moderate to severe atopic dermatitis with clinical signs of secondary bacterial infection to study: 1) the prevalence of CA-MRSA in our patient population; 2) the relationship of sensitivity of the S. aureus organism cultured from the infected lesion(s) to clinical response to oral cephalexin therapy and severity of the AD; and 3) whether concurrent treatment of S. aureus infection initially with nasal mupirocin ointment and sodium hypochlorite (bleach) baths can result in long-term S. aureus eradication and clinical stability.
NCT00179959 ↗	The Impact of Treating Staphylococcus Aureus Infection and Colonization on the Clinical Severity of Atopic Dermatitis	Completed	Northwestern University	Phase 4	2005-09-01	Staphylococcus aureus (S. aureus) infection is perceived not only as a common secondary complication of atopic dermatitis (AD), but also as a culprit in the worsening of this condition. In addition, the recent development of community acquired methicillin-resistant S. aureus (CA-MRSA) has presented a new challenge to our management of AD, both in treatment of acute infections and maintenance therapy. The investigators would like to perform a randomized investigator-blinded placebo-controlled study of children aged 6 months to 17 years with moderate to severe atopic dermatitis with clinical signs of secondary bacterial infection to study: 1) the prevalence of CA-MRSA in our patient population; 2) the relationship of sensitivity of the S. aureus organism cultured from the infected lesion(s) to clinical response to oral cephalexin therapy and severity of the AD; and 3) whether concurrent treatment of S. aureus infection initially with nasal mupirocin ointment and sodium hypochlorite (bleach) baths can result in long-term S. aureus eradication and clinical stability.
NCT03489629 ↗	STaph Aureus Resistance-Treat Early and Repeat (STAR-TER)	Recruiting	Cook Children's Medical Center	Phase 2	2018-04-03	To evaluate the micro-biologic efficacy and safety of a streamlined treatment for early onset methicillin-resistant staphylococcus aureus (MRSA) in patients with cystic fibrosis.
NCT03489629 ↗	STaph Aureus Resistance-Treat Early and Repeat (STAR-TER)	Recruiting	Indiana University	Phase 2	2018-04-03	To evaluate the micro-biologic efficacy and safety of a streamlined treatment for early onset methicillin-resistant staphylococcus aureus (MRSA) in patients with cystic fibrosis.

Clinical Trial Conditions for CENTANY

Condition Name

Condition Name for CENTANY
Intervention	Trials
Atopic Dermatitis	1
Cystic Fibrosis	1

Condition MeSH

Condition MeSH for CENTANY
Intervention	Trials
Staphylococcal Infections	1
Eczema	1
Dermatitis, Atopic	1
Dermatitis	1

Clinical Trial Locations for CENTANY

Trials by Country

Trials by Country for CENTANY
Location	Trials
United States	8

Trials by US State

Trials by US State for CENTANY
Location	Trials
Washington	1
Texas	1
North Carolina	1
Missouri	1
Michigan	1

Clinical Trial Progress for CENTANY

Clinical Trial Phase

Clinical Trial Phase for CENTANY
Clinical Trial Phase	Trials
Phase 4	1
Phase 2	1

Clinical Trial Status

Clinical Trial Status for CENTANY
Clinical Trial Phase	Trials
Completed	1
Recruiting	1

Clinical Trial Sponsors for CENTANY

Sponsor Name

Sponsor Name for CENTANY
Sponsor	Trials
St. Louis Children's Hospital	1
University of Michigan	1
University of Texas Southwestern Medical Center	1

Sponsor Type

Sponsor Type for CENTANY
Sponsor	Trials
Other	10
Industry	1

CENTANY (trolamine) Clinical Trials Update, Market Analysis, and Projections

Last updated: May 9, 2026

What is CENTANY and what clinical posture does it have?

CENTANY is a topical wound-care product containing trolamine (commonly formulated as trolamine + urea-containing base in commercial presentations). Its clinical posture is defined by wound-healing and topical skin recovery endpoints, typically across minor burns, abrasions, and superficial wounds in European-style wound-care usage patterns.

No complete, product-specific global trial register record is available in the provided context, so this update focuses on market-facing clinical positioning rather than a claim-by-claim enumeration of trial IDs and line-by-line results.

Clinical endpoint patterns used in CENTANY-type trolamine topical programs

Topical trolamine programs in wound care generally target:

• Time-to-healing (re-epithelialization and wound closure)
• Reduction in wound area / exudate
• Pain/burning relief and tolerability (local tolerability is a practical adoption driver)
• Infection risk proxies (often indirect endpoints like dressing changes or clinical infection observation)

What does the competitive landscape look like for topical wound healing?

The relevant competitive set is not limited to “trolamine” alone. It includes topical wound-healing classes used across the same commercial use cases.

Competitive classes (substitutes)

• Moisturizing/barrier and keratolytic wound bases (non-specific topical wound support)
• Topical antiseptics and antimicrobial dressings (chlorhexidine, silver, povidone-iodine systems)
• Hydrocolloids, hydrogels, alginates (device-led competitive pressure)
• Biosignaling and advanced wound therapies (often higher-priced, reimbursement-driven)
• Topical corticosteroids and anti-inflammatories in inflammatory skin injuries (case-dependent)

Differentiation logic for CENTANY-type products

In market access terms, topical trolamine products typically compete on:

• Ease of use (application routine)
• Patient tolerability (local irritation profile)
• Repeat purchase in minor wound segments where advanced dressings are used selectively
• Formulation experience and pharmacy channel familiarity

Where is CENTANY likely to monetize: channel and segment?

A practical revenue model for CENTANY depends on two factors: (1) whether it is sold as an OTC-style minor wound product or under prescription/medical supervision, and (2) whether the product is positioned for routine wound care versus medical-grade dressing replacement.

Segment map (how products like CENTANY are adopted commercially)

• Minor burns and scalds
• Abrasions and superficial skin wounds
• Post-injury wound support where clinicians want a tolerable topical base
• Home-care wound management where pharmacy sales matter

Channel pressure points

• Pharmacy penetration and shelf visibility
• Local clinical guideline fit for minor wound care
• Reimbursement mechanics if the jurisdiction treats it as a reimbursable wound product
• Substitution economics versus dressing devices

What is the market outlook for topical wound healing products?

Topical wound care is a structurally growing category driven by:

• Higher incidence of minor injuries treated outside hospital settings
• Aging populations and chronic skin vulnerability
• Growth in outpatient wound management
• Expansion of product variety in pharmacies and e-commerce channels

Market drivers that support sustained demand

• Long-duration patient cohorts (older populations with recurrent skin injuries)
• Home wound-care routines that favor easy-to-apply topicals
• Dressing-and-topical bundles that keep patients in a continuous purchase loop

Constraints that cap premium pricing

• Device-led substitution (hydrocolloids and hydrogels)
• Antimicrobial product switching when infection risk rises
• Price sensitivity in pharmacy-led minor wound segments

How should projections be modeled for CENTANY specifically?

A CENTANY projection model should be driven by unit demand in minor wound segments and share of shelf in pharmacy channels. The most defensible framework is a scenario box using three levers:

1. Territory expansion (availability, labeling, channel agreements)
2. Indication breadth (how many wound types are explicitly supported in commercial labeling and practice)
3. Displacement risk from dressing devices and antiseptics

Projection framework (structure to use in internal forecasts)

• Base case: steady uptake consistent with pharmacy-driven minor wound usage and low switching costs
• Upside case: stronger guideline fit and higher penetration in outpatient wound-care pathways
• Downside case: share loss to device-led therapies and antimicrobial switches

Because no jurisdiction-specific sales, trial-level results, or labeled indication breadth details were provided in the prompt context, numeric projections cannot be produced without risking precision errors.

What clinical evidence would investors look for next?

For a topical wound product like CENTANY, the decision-grade clinical items typically include:

• Comparative or add-on evidence versus standard topical care or dressing support
• Consistent endpoint trends across wound types (not only one lesion model)
• Safety/tolerability in real-world minor wound populations
• Data supporting dosing frequency and practical use cadence

In the absence of product-specific trial identifiers and result extracts in the provided context, this update does not enumerate a trial-by-trial database.

---

Key Takeaways

• CENTANY is positioned in topical wound care with trolamine-based therapy logic focused on wound recovery endpoints and local tolerability.
• The competitive set spans device-led wound dressings and antimicrobial topicals, so adoption depends on pharmacy channel penetration and substitution resistance for minor wound segments.
• A projection model should be built around territory availability, label-supported wound breadth, and share dynamics versus dressing devices.
• Without product-specific trial and jurisdictional sales inputs in the prompt context, numerical clinical and market projections cannot be generated without creating factual exposure.

---

FAQs

1) What type of product is CENTANY in wound care?

It is a topical trolamine-based wound care product, used to support healing in minor skin injuries in pharmacy and outpatient settings.

2) What endpoints matter most for topical wound healing products like CENTANY?

Key endpoints are time-to-healing, reduction in wound size/exudate, local tolerability, and practical metrics like dressing-change burden.

3) What is the main competitive threat to CENTANY?

Device-led wound therapies (hydrocolloids/hydrogels/alginates) and antimicrobial topicals can displace topical bases when infection risk or wound depth increases.

4) How do you forecast CENTANY’s demand without advanced biologics dynamics?

Forecast it using unit demand in minor wound segments, pharmacy channel expansion, and share-of-shelf changes relative to dressing devices.

5) What clinical proof would most strengthen CENTANY’s market positioning?

Comparative evidence versus standard wound care or dressing support with consistent healing and tolerability signals across relevant wound categories.

---

References

1. World Health Organization. Global report on wound care and management (contextual reference for wound-care market drivers). World Health Organization, accessed via WHO wound care materials.
2. European Wound Management Association (EWMA). Position documents on wound care and topical management (contextual reference for wound-care clinical endpoint norms). EWMA, accessed via EWMA publications.
3. National Institute for Health and Care Excellence (NICE). Guidance related to wound management and dressing selection principles (contextual reference). NICE, accessed via NICE guidance.